No Data
No Data
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?
Truist Financial Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating
Truist Financial Keeps Their Buy Rating on Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now
No Data
No Data